TOKYO, Japan – December 2, 2014 – Astellas Pharma Inc. announced that its license contract with Janssen Biotech, Inc. to develop and commercialize ASP015K, Astellas’ oral Janus Kinase inhibitor, january 15 will end effective, 2015. Janssen offers exercised its right to terminate the license agreement, that was signed in 2012. Upon the effective date of termination, Astellas will regain all privileges granted to Janssen. Astellas is now taking into consideration the future arrange for ASP015K outside Japan, but will continue the Phase 3 development program that was initiated in Japan. Upon the termination of the permit agreement, Astellas will not revise its financial forecast for the existing fiscal season .‘Perhaps we could live with all these adverse drug reactions if statins considerably lowered the risk for cardiovascular disease. But, they don’t,’ wrote Dr. Brownstein on his blog page. ‘Statins have never been convincingly proven to prevent a first heart attack in men and women. In men, the best of the statin studies show a 1-4 percent reduced risk of preventing a secondary cardiac event. In women, the real numbers are worse.’ This is extremely disconcerting in light of phone calls by some doctors for statins to end up being handed out like candy, or actually dripped into public drinking water supplies alongside fluoride. This so-called ‘medicine’ is normally wreaking havoc on open public health, and it generally does not even provide any legitimate therapeutic benefits.